Zealand Pharma As Stock Price To Sales
| ZEAL Stock | DKK 726.50 29.50 4.23% |
Zealand Pharma AS fundamentals help investors to digest information that contributes to Zealand Pharma's financial success or failures. It also enables traders to predict the movement of Zealand Stock. The fundamental analysis module provides a way to measure Zealand Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zealand Pharma stock.
Zealand |
Zealand Pharma AS Company Price To Sales Analysis
Zealand Pharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Zealand Pharma Price To Sales | 36.73 X |
Most of Zealand Pharma's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Zealand Pharma AS has a Price To Sales of 36.7281 times. This is 71.63% higher than that of the Healthcare sector and 62.68% lower than that of the Biotechnology industry. The price to sales for all Denmark stocks is notably lower than that of the firm.
Zealand Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zealand Pharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zealand Pharma could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics of similar companies.Zealand Pharma is currently under evaluation in price to sales category among its peers.
Zealand Fundamentals
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 10.33 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 12.66 X | |||
| Price To Book | 27.77 X | |||
| Price To Sales | 36.73 X | |||
| Revenue | 292.57 M | |||
| Gross Profit | 173.75 M | |||
| EBITDA | (982.6 M) | |||
| Net Income | (1.02 B) | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 29.66 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 4.19 X | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (23.13) X | |||
| Price To Earnings To Growth | 0.31 X | |||
| Target Price | 243.75 | |||
| Number Of Employees | 203 | |||
| Beta | 0.95 | |||
| Market Capitalization | 11.16 B | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | 154 M | |||
| Working Capital | 463 M | |||
| Current Asset | 517 M | |||
| Current Liabilities | 54 M | |||
| Z Score | 10.2 | |||
| Net Asset | 2.07 B |
About Zealand Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Zealand Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zealand Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zealand Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Zealand Stock
| 0.73 | NOVO-B | Novo Nordisk AS | PairCorr |
| 0.71 | GMAB | Genmab AS | PairCorr |
| 0.74 | ALK-B | ALK Abell AS | PairCorr |
| 0.72 | BAVA | Bavarian Nordic | PairCorr |
Moving against Zealand Stock
The ability to find closely correlated positions to Zealand Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zealand Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zealand Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zealand Pharma AS to buy it.
The correlation of Zealand Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zealand Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zealand Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zealand Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.